Please try another search
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
James N. Chang | 63 | 1997 | Chairman & Spokesperson |
Gwo-Fong Lin | 67 | 2020 | Independent Director |
Shih Chia Lin | - | 2022 | Director |
Hui-Chuan Chang | - | 2022 | Director |
Tien-Chieh Lee | 64 | 2021 | Director |
Chi-Chuan Chen | 66 | 2013 | Director |
Shiren S. Lee | 63 | 2017 | Independent Director |
Ta-mon Tseng | 66 | 2018 | Director |
Chin-Ting Chiu | - | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review